Nanomaterials for Fluorescence and Multimodal Bioimaging.
Jeladhara SobhananAbdulaziz AnasVasudevanpillai BijuPublished in: Chemical record (New York, N.Y.) (2023)
Bioconjugated nanomaterials replace molecular probes in bioanalysis and bioimaging in vitro and in vivo. Nanoparticles of silica, metals, semiconductors, polymers, and supramolecular systems, conjugated with contrast agents and drugs for image-guided (MRI, fluorescence, PET, Raman, SPECT, photodynamic, photothermal, and photoacoustic) therapy infiltrate into preclinical and clinical settings. Small bioactive molecules like peptides, proteins, or DNA conjugated to the surfaces of drugs or probes help us to interface them with cells and tissues. Nevertheless, the toxicity and pharmacokinetics of nanodrugs, nanoprobes, and their components become the clinical barriers, underscoring the significance of developing biocompatible next-generation drugs and contrast agents. This account provides state-of-the-art advancements in the preparation and biological applications of bioconjugated nanomaterials and their molecular, cell, and in vivo applications. It focuses on the preparation, bioimaging, and bioanalytical applications of monomodal and multimodal nanoprobes composed of quantum dots, quantum clusters, iron oxide nanoparticles, and a few rare earth metal ion complexes.
Keyphrases
- quantum dots
- single molecule
- living cells
- energy transfer
- fluorescence imaging
- photodynamic therapy
- fluorescent probe
- magnetic resonance
- contrast enhanced
- sensitive detection
- iron oxide nanoparticles
- computed tomography
- magnetic resonance imaging
- cancer therapy
- cell therapy
- single cell
- pet ct
- gene expression
- stem cells
- positron emission tomography
- oxidative stress
- drug delivery
- cell proliferation
- mesenchymal stem cells
- drug induced
- nucleic acid
- staphylococcus aureus
- circulating tumor
- amino acid
- heavy metals
- water soluble
- liquid chromatography
- health risk assessment